Argus Research analyst Steve Silver downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Sell.
Argus Research Downgrades Silk Road Medical to Sell
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.